AbbVie forms $30M research partnership with Harvard Medical School
Photo | Grant Welker
AbbVie's Worcester facility
Illinois biomedical company AbbVie, which has facilities in Worcester, announced on Tuesday a $30-million collaborative research alliance with Harvard Medical School in Boston to study and develop novel therapies against emergent viral infections.
The alliance will specifically focus on those caused by coronaviruses and viruses leading to hemorrhagic fever, according to a press release.
“A key element of having a strong R&D organization is collaboration with top academic institutions, like Harvard Medical School, to develop therapies for patients who need them most,” said Michael Severino, AbbVie vice chairman and president, in a statement.
AbbVie will provide $30 million over three years, as well as assistance from its scientists and other resources to help advance collaborative research dn early-stage development efforts across five program areas, including immunity and immunopathology, host targeting for antiviral therapies, antibody therapeutics, small molecules and translational development.
WBJ Web Partners
Most Recent
Most Recent
0 Comments